HXHai-Fei Xiang

Hai-Fei Xiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hai-Fei Xiang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Chun-Lian Zhou

    Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University

    1 shared publication
  • Feng Lin

    Department of Anesthesiology, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou 317000, China

    1 shared publication
  • Feng Lin

    Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University

    1 shared publication
  • Guo Yu

    Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University

    1 shared publication
  • Jian-Bin Cao

    Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University

    1 shared publication
  • Jun-Ming Chen

    Department of Anaesthesiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University

    1 shared publication

Latest Publications

  • Open Access

    Efficacy and safety of remimazolam for sedation during gynaecologic procedures: a systematic review and meta-analysis

    by Guo Yu, Chun-Lian Zhou, Min-Shu Zhu, Rui Lu, Jun-Ming Chen, Jian-Bin Cao, Feng Lin, Hai-Fei Xiang

    The efficacy of remimazolam compared to propofol for sedation during gynaecologic procedures remains unknown, due to the increased severity of pain associated with these procedures. Therefore, a systematic review and meta-analysis was conducted to address this issue. The protocol has been registered with PROSPERO, number CRD42024511475. Medline/PubMed, Cochrane Library, Embase, Scopus and Web of Science were searched to identify randomized controlled trials (RCTs) covering the period up to 10 January 2025. The primary outcomes comprised the success rate of sedation and the incidence of body movement. Secondary outcomes included recovery time and incidence of adverse effects (i.e. hypotension, bradycardia, respiratory depression, postoperative nausea and vomiting (PONV), dizziness, hiccup and injection pain). Nine RCTs (1129 patients) were included in this meta-analysis. There were no significant differences for the success rate of sedation (RR = 0.98, 95% confidence interval (CI) 0.96-1.00) or the incidence of body movement (RR = 1.03, 95% CI 0.49-2.14). Remimazolam had a lower incidence of adverse effects, including hypotension (RR = 0.21, 95% CI 0.11-0.41), bradycardia (RR = 0.12, 95% CI 0.02-0.97), respiratory depression (RR = 0.30, 95% CI 0.15-0.61), injection pain (RR = 0.06, 95% CI 0.02-0.17) and dizziness (RR = 0.29, 95% CI 0.10-0.82). However, remimazolam increased the incidence of hiccup (RR = 10.16, 95% CI 2.48-41.61). No significant differences were found regarding the recovery time (MD = 1.58, 95% CI -0.20 to 3.35) or the incidence of PONV (RR = 0.68, 95% CI 0.15-3.05). In gynaecologic procedures, remimazolam has comparable efficacy to propofol in the success rate of sedation and the incidence of body movement, while exhibiting superior respiratory and cardiovascular safety profiles. These findings should be cautiously generalized to other populations, and warrant further validation.